<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">J. Infect. Dis</journal-id><journal-id journal-id-type="publisher-id">jid</journal-id><journal-title-group><journal-title>The Journal of Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">0022-1899</issn><issn pub-type="epub">1537-6613</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29390150</article-id><article-id pub-id-type="pmc">5894073</article-id><article-id pub-id-type="doi">10.1093/infdis/jiy054</article-id><article-id pub-id-type="publisher-id">jiy054</article-id><article-categories><subj-group subj-group-type="heading"><subject>Major Articles and Brief Reports</subject><subj-group subj-group-type="category-toc-heading"><subject>Viruses</subject></subj-group></subj-group></article-categories><title-group><article-title>Histo&#x02013;Blood Group Antigen Phenotype Determines Susceptibility to Genotype-Specific Rotavirus Infections and Impacts Measures of Rotavirus Vaccine Efficacy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="corresp" rid="c1"/><!--<email>benjamin.lee.1@med.uvm.edu</email>--></contrib><contrib contrib-type="author"><name><surname>Dickson</surname><given-names>Dorothy M</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>deCamp</surname><given-names>Allan C</given-names></name><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Ross Colgate</surname><given-names>E</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Diehl</surname><given-names>Sean A</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Uddin</surname><given-names>Muhammad Ikhtear</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Sharmin</surname><given-names>Salma</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Islam</surname><given-names>Shahidul</given-names></name><xref ref-type="aff" rid="AF0004">4</xref><xref ref-type="author-notes" rid="fn-0001"/></contrib><contrib contrib-type="author"><name><surname>Bhuiyan</surname><given-names>Taufiqur Rahman</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Alam</surname><given-names>Masud</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Nayak</surname><given-names>Uma</given-names></name><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Mychaleckyj</surname><given-names>Josyf C</given-names></name><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Taniuchi</surname><given-names>Mami</given-names></name><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Petri</surname><given-names>William A</given-names><suffix>Jr</suffix></name><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Haque</surname><given-names>Rashidul</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Qadri</surname><given-names>Firdausi</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Kirkpatrick</surname><given-names>Beth D</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>Vaccine Testing Center, 1Department of Pediatrics</aff><aff id="AF0002"><label>2</label>Department of Medicine, University of Vermont Larner College of Medicine, Burlington</aff><aff id="AF0003"><label>3</label>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington</aff><aff id="AF0004"><label>4</label>International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka</aff><aff id="AF0005"><label>5</label>Center for Public Health Genomics and Department of Public Health Sciences</aff><aff id="AF0006"><label>6</label>Division of Infectious Diseases and International Health, University of Virginia, Charlottesville</aff><author-notes><fn id="fn-0001"><p>Present affiliation: Department of Vascular Physiology, Graduate School of Medicine, Kanazawa University, Japan.</p></fn><corresp id="c1">Correspondence: B. Lee, MD, University of Vermont Vaccine Testing Center, Department of Pediatrics, University of Vermont Larner College of Medicine, 89 Beaumont Ave, Given C219, Burlington, VT 05405 (<email>benjamin.lee.1@med.uvm.edu</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="epub" iso-8601-date="2018-01-30"><day>30</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>1</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>217</volume><issue>9</issue><fpage>1399</fpage><lpage>1407</lpage><history><date date-type="received"><day>16</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>25</day><month>1</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.</copyright-statement><copyright-year>2018</copyright-year><license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="jiy054.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Lewis and secretor histo&#x02013;blood group antigens (HBGAs) have been associated with decreased susceptibility to P[8] genotype rotavirus (RV) infections. Efficacy of vaccines containing attenuated P[8] strains is decreased in low-income countries. Host phenotype might impact vaccine efficacy (VE) by altering susceptibility to vaccination or RV diarrhea (RVD). We performed a substudy in a monovalent RV vaccine (RV1) efficacy trial in Bangladesh to determine the impact of Lewis and secretor status on risk of RVD and VE.</p></sec><sec id="s2"><title>Methods</title><p>In infants randomized to receive RV1 or no RV1 at 10 and 17 weeks with 1 year of complete active diarrheal surveillance, we performed Lewis and secretor phenotyping and genotyped the infecting strain of each episode of RVD.</p></sec><sec id="s3"><title>Results</title><p>A vaccine containing P[8] RV protected secretors and nonsecretors similarly. However, unvaccinated nonsecretors had a reduced risk of RVD (relative risk, 0.53 [95% confidence interval, .36&#x02013;.79]) mediated by complete protection from P[4] but not P[8] RVs. This effect reduced VE in nonsecretors to 31.7%, compared to 56.2% among secretors, and decreased VE for the overall cohort.</p></sec><sec id="s4"><title>Conclusions</title><p>Host HBGA status may impact VE estimates by altering susceptibility to RV in unvaccinated children; future trials should therefore account for HBGA status.</p></sec><sec id="s5"><title>Clinical Trials Registration</title><p>NCT01375647.</p></sec></abstract><abstract abstract-type="teaser"><p>Histo&#x02013;blood group antigens were associated with genotype-specific susceptibility to rotavirus infections. Nonsecretors were at decreased risk of P[4] infections, while Lewis-negative children were at increased risk of P[6] infections. These effects may impact oral rotavirus vaccine efficacy estimates.</p></abstract><kwd-group><kwd>rotavirus</kwd><kwd>secretor</kwd><kwd>Lewis</kwd><kwd>vaccination</kwd><kwd>vaccine efficacy</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">Bill and Melinda Gates Foundation</named-content><named-content content-type="funder-identifier">10.13039/100000865</named-content></funding-source><award-id>OPP1127782</award-id><award-id>OPP1017093</award-id></award-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">National Institutes of Health</named-content><named-content content-type="funder-identifier">10.13039/100000002</named-content></funding-source><award-id>AI043596</award-id></award-group></funding-group><counts><page-count count="9"/></counts></article-meta></front><body><p>Rotavirus (RV) remains the leading cause of infectious diarrhea among infants worldwide [<xref rid="CIT0001" ref-type="bibr">1</xref>]. Oral, live-attenuated RV vaccines such as Rotarix (RV1, GlaxoSmithKline) and RotaTeq (RV5, Merck) have markedly reduced the burden of RV diarrhea (RVD), but RV still causes nearly 215000 deaths yearly among children worldwide, primarily in low-income countries (LICs) in Asia and sub-Saharan Africa [<xref rid="CIT0002" ref-type="bibr">2</xref>]. For reasons not completely understood, oral RV vaccines have demonstrated reduced vaccine efficacy (VE) and effectiveness in countries with high child mortality, where disease burden remains highest [<xref rid="CIT0003" ref-type="bibr">3</xref>].</p><p>RVs are triple-layered particles with an outer capsid layer comprised of VP4, a protease-sensitive protein (P) spike, and VP7, a glycoprotein (G) shell. RVs are typically classified by G and P genotypes; for example, RV1 contains a G1P[8] strain. The VP8* subunit of VP4 binds histo&#x02013;blood group antigens (HBGAs) present on enterocyte surfaces, suggesting an important role for HBGAs in the pathogenesis of RV infection [<xref rid="CIT0004" ref-type="bibr">4</xref>]. HGBAs are glycans ubiquitously found on mucosal surfaces and in exocrine secretions, including in the gut [<xref rid="CIT0005" ref-type="bibr">5</xref>]. Increasing evidence suggests that susceptibility to infection with specific RV P genotypes is associated with HBGAs determined by secretor status and Lewis (Le) phenotype [<xref rid="CIT0006" ref-type="bibr">6</xref>], controlled by the FUT2 and FUT3 genes, respectively.</p><p>An overview of secretor and Le phenotypes is provided in <xref ref-type="supplementary-material" rid="sup3">Supplementary Figure 1</xref>. FUT2 encodes an &#x003b1;[1,2]-fucosyltransferase that modifies precursor oligosaccharides to form the H-type antigen. Individuals expressing an active allele are termed secretors (<italic>Se</italic>), while those with a null phenotype are termed nonsecretors (<italic>se</italic>) and cannot express H-type antigens in the gut. FUT3 encodes an &#x003b1;[1,3/4]-fucosyltransferase that modifies precursor oligosaccharides or H-type antigens to form the Le<sup>a</sup> or Le<sup>b</sup> antigens, respectively. Lewis phenotype is thus determined by the action of both FUT2 and FUT3. However, Lewis-negative individuals (Le<sup>&#x02013;</sup>) express neither Le<sup>a</sup> nor Le<sup>b</sup>, irrespective of secretor status [<xref rid="CIT0005" ref-type="bibr">5</xref>].</p><p>Previous studies suggest that nonsecretors and Le<sup>&#x02013;</sup> individuals may be resistant to infection with P[8] and P[4] RVs [<xref rid="CIT0007" ref-type="bibr">7&#x02013;10</xref>], whereas risk of P[6] RV infection may be increased in Le<sup>&#x02013;</sup> individuals [<xref rid="CIT0011" ref-type="bibr">11</xref>]. This may explain the high frequency of P[6] infections in Africa, where Le<sup>&#x02013;</sup> phenotypes are also more frequent [<xref rid="CIT0011" ref-type="bibr">11</xref>, <xref rid="CIT0012" ref-type="bibr">12</xref>]. As both RV1 and RV5 contain attenuated P[8] RVs, it has been proposed that resistance to P[8] RVs could cause resistance to vaccination and subsequent vaccine failure due to lack of protection against non-P[8] RVs. In regions with high frequencies of nonsecretors or Le<sup>&#x02013;</sup> individuals, this could decrease VE. Because risk among unvaccinated individuals is required to calculate VE, HBGA-mediated differences in susceptibility to RV infection among unvaccinated participants may also have unexpected implications in the analysis of RV vaccine trials.</p><p>Despite these important potential effects, the contribution of secretor status and Lewis phenotype to decreased oral RV VE in LICs has yet to be investigated. To determine the effects of secretor status and Lewis phenotype on susceptibility to natural RV infection and oral RV vaccine underperformance, we conducted a substudy among infants participating in an RV1 efficacy trial in Dhaka, Bangladesh.</p><sec sec-type="methods" id="s6"><title>METHODS</title><sec id="s7"><title>Study Population and Procedures</title><p>We performed a substudy within Performance of Rotavirus and Oral Polio Vaccines in Developing Countries (PROVIDE), an RV1 VE trial conducted in urban Dhaka, Bangladesh from 2010 to 2014. PROVIDE was approved by the ethical review boards of the International Centre for Diarrhoeal Disease Research, Bangladesh, the University of Vermont, and the University of Virginia and was registered at ClinicalTrials.gov (NCT01375647). All participating families provided signed informed consent. Seven hundred infants were enrolled within 7 days of life, randomized 1:1 to receive RV1 or no RV1 at 10 and 17 weeks, and followed with active community-based diarrheal surveillance. RVD was determined by RV antigen detection in diarrheal specimens using the ProSpecT enzyme immunoassay kit (Oxoid, Hampshire, UK). Severe RVD was defined as Vesikari score &#x02265;11 [<xref rid="CIT0013" ref-type="bibr">13</xref>]. Saliva was collected at 1 and 2 years of life using the SalivoBio infant swab collection kit (Salimetrics, Carlsbad, California). Study design, detailed methods, and primary efficacy results have been reported [<xref rid="CIT0014" ref-type="bibr">14&#x02013;16</xref>]. For this substudy, we identified infants with complete 1-year follow-up, sufficient saliva for phenotyping, and who received both doses of RV1 (for vaccinated infants) per protocol. Within this subpopulation, we performed RV genotyping and HBGA phenotyping as detailed below.</p></sec><sec id="s8"><title>Rotavirus P Genotyping</title><p>RVD stool specimens underwent total nucleic acid extraction using the QIAamp Fast DNA Stool Mini Kit (Qiagen, Hilden, Germany) [<xref rid="CIT0017" ref-type="bibr">17</xref>]. Reverse-transcription polymerase chain reaction (RT-PCR) was performed on total nucleic acid extracts to amplify the VP8* segment of VP4 as previously described [<xref rid="CIT0018" ref-type="bibr">18</xref>]. Resulting amplicons underwent Sanger sequencing using the VP4F primer on the ABI PRISM 3130xl Genetic Analyzer (Applied Biosystems, Foster City, California). Sequences were analyzed using BioEdit version 7.2.5 (Ibis BioSciences, Carlsbad, California), followed by BLAST analysis to determine the P genotype of each infecting strain.</p></sec><sec id="s9"><title>Secretor Status and Lewis Antigen Phenotyping</title><p>Le<sup>a</sup> and Le<sup>b</sup> antigen phenotyping was performed on stored saliva specimens using a dot-blot assay as previously described [<xref rid="CIT0019" ref-type="bibr">19</xref>]. Infants were defined as Le<sup>+</sup> if either Le<sup>a</sup> or Le<sup>b</sup> antigen was detected (<xref ref-type="table" rid="T1">Table 1</xref>). Secretor status was inferred from Lewis phenotyping: Le<sup>a+b&#x02013;</sup> infants were defined as <italic>se</italic>; Le<sup>a&#x02013;b+</sup> and Le<sup>a+b+</sup> (partial-secretor) infants were defined as <italic>Se</italic>. Among Le<sup>a&#x02013;b&#x02013;</sup> infants, <italic>Ulex europaeus</italic> agglutinin enzyme immunoassay was performed to confirm secretor status as previously described [<xref rid="CIT0011" ref-type="bibr">11</xref>]. A specimen was defined as <italic>Se</italic> if the optical density (OD) was &#x02265;0.09 (&#x02265;3 standard deviations above the mean OD calculated for multiple replicates of blank wells). For verification, 25 Le<sup>a&#x02013;b+</sup> and 27 Le<sup>a+b&#x02013;</sup> specimens were tested; all Le<sup>a&#x02013;b+</sup> were confirmed as <italic>Se</italic> (minimum OD = 0.114), and all Le<sup>a+b&#x02013;</sup> were confirmed as <italic>se</italic> (maximum OD = 0.071).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Summary of Secretor Status and Lewis Antigen Phenotypes</p></caption><table frame="vsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Phenotype</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total (N = 550)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Unvaccinated<sup>a</sup> (n = 275)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Vaccinated<sup>a</sup><break/>(n = 275)</th></tr></thead><tbody><tr><td colspan="4" rowspan="1">Secretor status</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic>Se</italic></td><td rowspan="1" colspan="1">371 (67.5)</td><td rowspan="1" colspan="1">182 (66.2)</td><td rowspan="1" colspan="1">189 (68.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic>se</italic></td><td rowspan="1" colspan="1">179 (32.5)</td><td rowspan="1" colspan="1">93 (33.8)</td><td rowspan="1" colspan="1">86 (31.3)</td></tr><tr><td colspan="4" rowspan="1">Lewis phenotype</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Le+ (Le<sup>a+b&#x02013;</sup>, Le<sup>a&#x02013;b+</sup>, or Le<sup>a+b+</sup>)</td><td rowspan="1" colspan="1">469 (85.3)</td><td rowspan="1" colspan="1">241 (87.6)</td><td rowspan="1" colspan="1">228 (82.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Le<sup>&#x02013;</sup></td><td rowspan="1" colspan="1">81 (14.7)</td><td rowspan="1" colspan="1">34 (12.4)</td><td rowspan="1" colspan="1">47 (17.1)</td></tr><tr><td colspan="4" rowspan="1">Combined</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic>Se</italic>/Le<sup>+</sup> (Le<sup>a&#x02013;b+</sup> or Le<sup>a+b+</sup>)</td><td rowspan="1" colspan="1">314 (57.1)</td><td rowspan="1" colspan="1">159 (57.8)</td><td rowspan="1" colspan="1">155 (56.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic>Se</italic>/Le<sup>&#x02013;</sup> (Le<sup>a&#x02013;b&#x02013;</sup>)</td><td rowspan="1" colspan="1">57 (10.4)</td><td rowspan="1" colspan="1">23 (8.4)</td><td rowspan="1" colspan="1">34 (12.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic>se</italic>/Le<sup>+</sup> (Le<sup>a+b&#x02013;</sup>)</td><td rowspan="1" colspan="1">155 (28.2)</td><td rowspan="1" colspan="1">82 (29.8)</td><td rowspan="1" colspan="1">73 (26.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic>se</italic>/Le<sup>&#x02013;</sup> (Le<sup>a&#x02013;b&#x02013;</sup>)</td><td rowspan="1" colspan="1">24 (4.4)</td><td rowspan="1" colspan="1">11 (4)</td><td rowspan="1" colspan="1">13 (4.7)</td></tr></tbody></table><table-wrap-foot><fn id="fn-01"><p>Data are presented as No. (%).</p></fn><fn id="fn-02"><p>Abbreviations: Le<sup>+</sup>, Lewis-positive; Le<sup>&#x02013;</sup>, Lewis-negative; <italic>Se</italic>, secretor; <italic>se</italic>, nonsecretor.</p></fn><fn id="fn-03"><p>
<sup>a</sup>All differences are nonsignificant.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s10"><title>Statistical Analysis</title><p>Categorical outcomes were assessed using &#x003c7;<sup>2</sup> or Fisher exact test to estimate proportion difference with corresponding 95% confidence intervals (CIs) and associated relative risk (RR). Adjustment for multiple comparisons and corresponding calculation of adjusted <italic>P</italic> values (<italic>Q</italic> values) was performed using the Benjamini&#x02013;Hochberg procedure [<xref rid="CIT0020" ref-type="bibr">20</xref>]. Univariate and multivariable logistic regression was used to analyze the contributions of pertinent variables to protection from RVD and to test for interactions between variables. The primary outcome was any episode of RVD in the first year of life, except if vaccination was included as a variable, in which case the primary outcome was any episode of RVD from week 18 through week 52 of life (1 week postvaccination through 1 year). VE was calculated as [(risk among unvaccinated &#x02013; risk among vaccinated) / risk among unvaccinated]. Kaplan&#x02013;Meier estimators were used to calculate cumulative incidence of RVD by Lewis and secretor status. Differences between groups were tested using log-rank test. All analyses were performed using IBM SPSS software version 24 (IBM, Armonk, New York), GraphPad Prism version 7.01 (GraphPad Software, La Jolla, California), or SAS version 9.3 (SAS Institute, Cary, North Carolina). Differences were considered statistically significant at a 2-sided <italic>P</italic> value &#x0003c;.05.</p></sec></sec><sec id="s11"><title>RESULTS</title><sec id="s12"><title>Population Characteristics and P Genotypes of RVD Episodes</title><p>All 550 children identified (275 vaccinated, 275 unvaccinated) who met criteria for inclusion in this substudy were included in this analysis. Secretor status and Lewis antigen phenotypes of participants are summarized in <xref ref-type="table" rid="T1">Table 1</xref>; no differences were observed between unvaccinated and vaccinated infants. One hundred sixty-five infants experienced 174 episodes of RVD at any time during the first year of life (<xref ref-type="table" rid="T2">Table 2</xref>). One hundred eight infants experienced at least 1 episode of P[8] RVD, 19 had at least 1 episode of P[6] RVD, and 38 had at least 1 episode of P[4] RVD. Four children had 2 episodes of P[8] RVD, 4 children had P[8] RVD after infection with a different genotype, and 1 child had P[4] after an episode of P[8] RVD. Two episodes were due to P[25] RV; due to the small number of P[25] infections, these were excluded from subsequent genotype-specific analysis, but both infections occurred in Le<sup>+</sup> secretors. Three untypeable infections were also excluded from genotype-specific analyses; 2 occurred in Le<sup>+</sup> secretors and one in a Le<sup>+</sup> nonsecretor.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Infecting Rotavirus P Genotype Infants With Rotavirus Diarrhea in Year 1 of Life</p></caption><table frame="vsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Genotype</th><th align="center" valign="bottom" colspan="6" rowspan="1">Any Rotavirus Diarrhea, Year 1 of Life</th></tr><tr><th align="center" valign="bottom" colspan="3" rowspan="1">Unvaccinated, No. (%)</th><th align="center" valign="bottom" colspan="3" rowspan="1">Vaccinated, No. (%)</th></tr><tr><th valign="bottom" rowspan="1" colspan="1">P genotype</th><th align="center" valign="bottom" rowspan="1" colspan="1">First Episode (n = 103)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Second Episode (n = 5)</th><th align="center" valign="bottom" rowspan="1" colspan="1">All Episodes (n = 108)</th><th align="center" valign="bottom" rowspan="1" colspan="1">First Episode <break/>(n = 62)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Second Episode <break/>(n = 4)</th><th align="center" valign="bottom" rowspan="1" colspan="1">All Episodes <break/>(n = 66)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">&#x02003;P[4]</td><td rowspan="1" colspan="1">24 (23)</td><td rowspan="1" colspan="1">1 (20)</td><td rowspan="1" colspan="1">25 (23)</td><td rowspan="1" colspan="1">13 (21)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">13 (20)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;P[6]</td><td rowspan="1" colspan="1">9 (9)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">9 (8)</td><td rowspan="1" colspan="1">10 (16)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">10 (15)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;P[8]</td><td rowspan="1" colspan="1">68 (66)</td><td rowspan="1" colspan="1">4 (80)</td><td rowspan="1" colspan="1">72 (67)</td><td rowspan="1" colspan="1">36 (58)</td><td rowspan="1" colspan="1">4 (100)</td><td rowspan="1" colspan="1">40 (61)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;P[25]</td><td rowspan="1" colspan="1">1 (1)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">1 (1)</td><td rowspan="1" colspan="1">1 (2)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">1 (2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Untypeable</td><td rowspan="1" colspan="1">1 (1)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">1 (1)</td><td rowspan="1" colspan="1">2 (3)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">2 (3)</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" colspan="6" rowspan="1">Any Rotavirus Diarrhea, Weeks 18&#x02013;52 (Postvaccination)</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" colspan="3" rowspan="1">Unvaccinated, No. (%)</td><td align="center" colspan="3" rowspan="1">Vaccinated, No. (%)</td></tr><tr><td rowspan="1" colspan="1">P genotype</td><td align="center" rowspan="1" colspan="1">First Episode (n = 96)</td><td align="center" rowspan="1" colspan="1">Second Episode (n = 4)</td><td align="center" rowspan="1" colspan="1">Total Episodes (n = 100)</td><td align="center" rowspan="1" colspan="1">First Episode <break/>(n = 47)</td><td align="center" rowspan="1" colspan="1">Second Episode (n = 1)</td><td align="center" rowspan="1" colspan="1">Total Episodes <break/>(n = 48)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;P[4]</td><td rowspan="1" colspan="1">23 (24)</td><td rowspan="1" colspan="1">1 (25)</td><td rowspan="1" colspan="1">24 (24)</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">11 (23)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;P[6]</td><td rowspan="1" colspan="1">8 (8)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">8 (8)</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">7 (15)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;P[8]</td><td rowspan="1" colspan="1">65 (68)</td><td rowspan="1" colspan="1">3 (75)</td><td rowspan="1" colspan="1">68 (68)</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">1 (100)</td><td rowspan="1" colspan="1">28 (58)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;P[25]</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Untypeable</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">2 (4)</td></tr></tbody></table><table-wrap-foot><fn id="fn-04"><p>&#x0201c;First episode&#x0201d; refers to the first episode of rotavirus diarrhea experienced by an individual child. &#x0201c;Second episode&#x0201d; refers to the second episode of rotavirus diarrhea experienced by an individual child, and may be due to a different genotype than the first episode.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s13"><title>Secretor Status and Lewis Phenotype Have Distinct Effects on Risk of Natural RV Infection Among Unvaccinated Infants</title><p>We first assessed the role of secretor status and Lewis phenotype on risk of natural RV infection by analyzing the unvaccinated group. One hundred three unvaccinated infants (37.5%) had at least 1 episode of RVD; P[8] RV was most common, followed by P[4], then P[6] (<xref ref-type="table" rid="T2">Table 2</xref>). Significant differences were observed in frequency of RVD (<xref ref-type="table" rid="T3">Table 3</xref>) and time to first RVD according to combined secretor/Lewis phenotype (<italic>P</italic> = .003; <xref ref-type="fig" rid="F1">Figure 1</xref>).</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Frequency of Rotavirus Diarrhea Among Unvaccinated Infants According to Secretor/Lewis Phenotype</p></caption><table frame="vsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2" colspan="1">Phenotype</th><th align="center" valign="bottom" rowspan="2" colspan="1">Total(N = 275)</th><th align="center" valign="bottom" colspan="2" rowspan="1">Any RVD</th><th align="center" valign="bottom" colspan="2" rowspan="1">Severe RVD</th></tr><tr><th valign="bottom" rowspan="1" colspan="1">(n = 103)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>Q</italic> Value</th><th valign="bottom" rowspan="1" colspan="1">(n = 33)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>Q</italic> Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">&#x02003;<italic>Se</italic>/Le<sup>+</sup> (Le<sup>a&#x02013;b+</sup> or Le<sup>a+b+</sup>)</td><td rowspan="1" colspan="1">159 (58)</td><td rowspan="1" colspan="1">74 (72)</td><td rowspan="1" colspan="1">0.004</td><td rowspan="1" colspan="1">24 (73)</td><td rowspan="1" colspan="1">0.041</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic>Se</italic>/Le<sup>&#x02013;</sup> (Le<sup>a&#x02013;b&#x02013;</sup>)</td><td rowspan="1" colspan="1">23 (8)</td><td rowspan="1" colspan="1"> 7 (7)</td><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1"> 1 (3)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic>se</italic>/Le<sup>+</sup> (Le<sup>a+b&#x02013;</sup>)</td><td rowspan="1" colspan="1">82 (30)</td><td rowspan="1" colspan="1">18 (17)</td><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5 (15)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic>se</italic>/Le<sup>&#x02013;</sup> (Le<sup>a&#x02013;b&#x02013;</sup>)</td><td rowspan="1" colspan="1">11 (4)</td><td rowspan="1" colspan="1">4 (4)</td><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3 (9)</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="fn-05"><p>Data are presented as No. (%). <italic>Q</italic> values were calculated by adjustment of raw <italic>P</italic> values (Fisher exact test) for multiple comparisons by the Benjamini&#x02013;Hochberg procedure.</p></fn><fn id="fn-06"><p>Abbreviations: Le<sup>+</sup>, Lewis-positive; Le<sup>&#x02013;</sup>, Lewis-negative; RVD, rotavirus diarrhea; <italic>Se</italic>, secretor; <italic>se</italic>, nonsecretor.</p></fn></table-wrap-foot></table-wrap><fig fig-type="figure" id="F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Cumulative incidence of rotavirus diarrhea (RVD) in year 1 of life among unvaccinated infants according to secretor/Lewis phenotype. The distribution pattern of RVD incidence when comparing all groups together significantly differed according to phenotype. <italic>P</italic> value by Mantel&#x02013;Cox log-rank test. Abbreviations: Le<sup>+</sup>, Lewis-positive; Le<sup>&#x02013;</sup>, Lewis-negative; RVD, rotavirus diarrhea; <italic>Se</italic>, secretor; <italic>se</italic>, nonsecretor.</p></caption><graphic xlink:href="jiy05401"/></fig><p>When assessed by secretor status alone, nonsecretors had a significantly reduced risk of RVD (RR, 0.53 [95% CI, .36&#x02013;.79]) and were completely protected against P[4] RVD (<xref ref-type="table" rid="T4">Table 4</xref>). No differences were observed in risk of P[8] or P[6] RVD. Because a clear trend was detected for an interaction between secretor status and Lewis phenotype (<italic>P</italic> = .09) when tested by logistic regression, we stratified Le<sup>+</sup> vs Le<sup>&#x02013;</sup> phenotype by secretor status (<xref ref-type="table" rid="T4">Table 4</xref>). No differences were observed in overall risk of any RVD according to Le<sup>&#x02013;</sup> phenotype. However, Le<sup>&#x02013;</sup> infants were at significantly increased risk of P[6] RVD, irrespective of secretor status (<xref ref-type="table" rid="T4">Table 4</xref>) and for severe P[6] RVD (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 1</xref>). Le<sup>&#x02013;</sup> infants also tended to have fewer episodes of any or severe P[8] RVD.</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Risk of Rotavirus Diarrhea According to Secretor Status, Lewis Phenotype, and Rotavirus P Genotype Among Unvaccinated Infants in the First Year of Life</p></caption><table frame="vsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2" colspan="1">Phenotype</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total</th><th align="center" valign="bottom" colspan="3" rowspan="1">Any RVD<sup>a</sup></th><th align="center" valign="bottom" colspan="3" rowspan="1">P[8] RVD<sup>b</sup></th><th align="center" valign="bottom" colspan="3" rowspan="1">P[6] RVD<sup>b</sup></th><th align="center" valign="bottom" colspan="3" rowspan="1">P[4] RVD<sup>b</sup></th></tr><tr><th align="center" valign="bottom" rowspan="1" colspan="1">No. (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">No. (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">RR <break/>(95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>Q</italic> Value</th><th align="center" valign="bottom" rowspan="1" colspan="1">No. (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">RR <break/>(95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>Q</italic> Value</th><th align="center" valign="bottom" rowspan="1" colspan="1">No. (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">RR <break/>(95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>Q</italic> Value</th><th align="center" valign="bottom" rowspan="1" colspan="1">No. (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">RR <break/>(95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>Q</italic> Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic>Se</italic>
</td><td rowspan="1" colspan="1">182 (66)</td><td rowspan="1" colspan="1">81 (79)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">51 (73)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">6 (67)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">25 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<italic>se</italic>
</td><td rowspan="1" colspan="1">93 (34)</td><td rowspan="1" colspan="1">22 (21)</td><td rowspan="1" colspan="1">0.53 (.36&#x02013;.79)</td><td rowspan="1" colspan="1">0.003</td><td rowspan="1" colspan="1">19 (27)</td><td rowspan="1" colspan="1">0.73 (.46&#x02013;1.15)</td><td rowspan="1" colspan="1">0.22</td><td rowspan="1" colspan="1">3 (33)</td><td rowspan="1" colspan="1">0.97 (.25&#x02013;3.80)</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">275 (100)</td><td rowspan="1" colspan="1">103 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">70 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">9 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">25 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td colspan="14" rowspan="1">
<italic>Se</italic>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Le<sup>+</sup></td><td rowspan="1" colspan="1">159 (87)</td><td rowspan="1" colspan="1">74 (91)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">49 (96)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1 (17)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">25 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Le<sup>&#x02013;</sup></td><td rowspan="1" colspan="1">23 (13)</td><td rowspan="1" colspan="1">7 (9)</td><td rowspan="1" colspan="1">0.65 (.35&#x02013;1.24)</td><td rowspan="1" colspan="1">0.22</td><td rowspan="1" colspan="1">2 (4)</td><td rowspan="1" colspan="1">0.28 (.073&#x02013;1.08)</td><td rowspan="1" colspan="1">0.057</td><td rowspan="1" colspan="1">5 (83)</td><td rowspan="1" colspan="1">34.3 (4.20&#x02013;281)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">0.088</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Total</td><td rowspan="1" colspan="1">182 (100)</td><td rowspan="1" colspan="1">81 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">51 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">6 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">25 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td colspan="14" rowspan="1">
<italic>Se</italic>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Le<sup>+</sup></td><td rowspan="1" colspan="1">82 (88)</td><td rowspan="1" colspan="1">18 (82)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">18 (95)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Le<sup>&#x02013;</sup></td><td rowspan="1" colspan="1">11 (12)</td><td rowspan="1" colspan="1">4 (18)</td><td rowspan="1" colspan="1">1.66 (.69&#x02013;4.00)</td><td rowspan="1" colspan="1">0.34</td><td rowspan="1" colspan="1">1 (5)</td><td rowspan="1" colspan="1">0.41 (.061&#x02013;2.81)</td><td rowspan="1" colspan="1">0.50</td><td rowspan="1" colspan="1">3 (100)</td><td align="center" rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">0.003</td><td rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Total</td><td rowspan="1" colspan="1">93 (100)</td><td rowspan="1" colspan="1">22 (100</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">19 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="fn-07"><p>
<italic>Q</italic> values were calculated by adjustment of raw <italic>P</italic> values (&#x003c7;<sup>2</sup> or Fisher exact test) for multiple comparisons by the Benjamini&#x02013;Hochberg procedure.</p></fn><fn id="fn-08"><p>Abbreviations: CI, confidence interval; Le<sup>+</sup>, Lewis-positive; Le<sup>&#x02013;</sup>, Lewis-negative; NA, not applicable; RR, relative risk; RVD, rotavirus diarrhea; <italic>Se</italic>, secretor; <italic>se</italic>, nonsecretor.</p></fn><fn id="fn-09"><p>
<sup>a</sup>Refers to number of children who experienced at least 1 episode of RVD, irrespective of P genotype.</p></fn><fn id="fn-10"><p>
<sup>b</sup>Second episodes of RVD due to a different P genotype from the first are included, but second episodes due to the same P genotype are not since susceptibility to that specific P genotype had already been confirmed with the prior episode. One untypeable specimen and 1 P[25] infection were excluded. Therefore, the total number of P genotype&#x02013;specific episodes differs from the total number of children with any RVD.</p></fn></table-wrap-foot></table-wrap><p>All 25 P[4] infections among unvaccinated infants occurred exclusively in the <italic>Se</italic>/Le<sup>+</sup> population. To further assess whether this was mediated by secretor status or Lewis phenotype, we repeated our analyses with P[4] infections excluded. Nonsecretor status no longer conferred protection from RVD (RR, 0.80 [95% CI, .58&#x02013;1.12]), but no effect was observed for Lewis phenotype (data not shown), suggesting that risk of P[4] RVD appeared to be reflected mainly by secretor status, not by Lewis phenotype.</p></sec><sec id="s14"><title>Secretor Status Affects RV1 Vaccine Efficacy but Lewis Phenotype Does Not</title><p>We then examined the effects of RV1 on risk of RVD according to secretor status and Lewis phenotype. One hundred forty-three infants experienced at least 1 episode of RVD from week 18 to week 52 (1 week postvaccination through 1 year of life; <xref ref-type="table" rid="T2">Table 2</xref>). Vaccination was associated with a reduced risk of any RVD (RR, 0.49 [95% CI, .36&#x02013;.66]; <italic>Q</italic> &#x0003c; 0.001), RVD due to P[8] (RR, 0.42 [95% CI, .28&#x02013;.63]; <italic>Q</italic> &#x0003c; 0.001), and P[4] (RR, 0.46 [95% CI, .23&#x02013;.92]; <italic>Q</italic> = 0.031), but not P[6] (RR, 0.88 [95% CI, 0.32&#x02013;2.39]; <italic>Q</italic> = 0.79) RV (<xref ref-type="supplementary-material" rid="sup2">Supplementary Table 2</xref>). Similar findings were observed for severe RVD overall and for severe P[8] RVD.</p><p>In an unadjusted model, Lewis phenotype had no effect on cumulative incidence or time to first RVD for vaccinated or unvaccinated infants (<xref ref-type="fig" rid="F2">Figure 2A</xref>). There was no interaction between vaccination and Lewis phenotype (<italic>P</italic> = .86), indicating that Lewis phenotype did not modify the vaccine effect.</p><fig fig-type="figure" id="F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Cumulative incidence of rotavirus diarrhea (RVD) according to Lewis phenotype, secretor status, and vaccination status. Solid lines indicated unvaccinated infants; dashed lines indicate vaccinated infants. <italic>A</italic>, Lewis phenotype had no detectable effect modification on vaccine effect (<italic>P</italic> = .86), and was not associated with risk of RVD from week 18 to week 52 of life, irrespective of vaccination. <italic>B</italic>, Secretor status had a significant effect on RVD from week 18 to week 52 of life among unvaccinated infants but not among vaccinated infants. <italic>P</italic> values by Mantel&#x02013;Cox log-rank test. Abbreviations: CI, confidence interval; HR, hazard ratio; Le<sup>+</sup>, Lewis-positive; Le<sup>&#x02013;</sup>, Lewis-negative; RVD, rotavirus diarrhea; <italic>Se</italic>, secretor; <italic>se</italic>, nonsecretor.</p></caption><graphic xlink:href="jiy05402"/></fig><p>In contrast, secretor status had a strong effect on RVD among unvaccinated infants (<italic>P</italic> = .0004) but not vaccinated infants (<italic>P</italic> = .35) (<xref rid="F2" ref-type="fig">Figure 2B</xref>). In a multivariable logistic regression model including variables previously identified to impact risk of RVD in this [<xref rid="CIT0014" ref-type="bibr">14</xref>] and similar cohorts [<xref rid="CIT0021" ref-type="bibr">21</xref>] (week 18 serum zinc concentration, RV-specific immunoglobulin A [IgA] seroconversion, water treatment, exclusive breastfeeding until week 18 of life, prior RV infection, and stunting), a significant interaction was detected between vaccination and secretor status (<italic>P</italic> = .034). This confirmed that the effect of secretor status could not be interpreted independently of vaccination status. Therefore, separate multivariable models were run in unvaccinated and vaccinated infants to assess whether these additional variables would impact the results. After adjusting for these variables, secretor status was not associated with RVD in vaccinated infants (<italic>P</italic> = .5) but remained significantly associated with RVD in unvaccinated infants (<italic>P</italic> &#x0003c; .001). These results indicate that secretor status significantly modifies the effect of vaccination (ie, the effect of vaccination depended on secretor status). The risk reduction among unvaccinated nonsecretors (RR, 0.53 [95% CI, 0.36&#x02013;0.80]) approached that induced by vaccination among secretors (RR, 0.44 [95% CI, .31&#x02013;.62]). Although results should be interpreted with caution due to sample size, VE in nonsecretors (31.7% [95% CI, &#x02013;32.2% to 64.7%]) was reduced compared to secretors (56.2% [95% CI, 38.3%&#x02013;69%]). VE against severe RVD was 69.1% (95% CI, &#x02013;44.7 to 93.4%]) among nonsecretors and 79.1% (95% CI, 46.1%&#x02013;91.9%) among secretors.</p><p>Next, we assessed the risk of vaccine failure (ie, breakthrough RVD following vaccination) according to secretor status and Lewis phenotype; results are summarized in <xref ref-type="table" rid="T5">Table 5</xref>. There was no difference in risk of overall vaccine failure according to secretor status or Lewis phenotype. Le<sup>&#x02013;</sup> infants, however, had increased risk for P[6] vaccine failure, most significant among nonsecretors.</p><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Risk of Vaccine Failure According to Secretor Status, Lewis Phenotype, and Rotavirus P Genotype Among Vaccinated Infants, Weeks 18&#x02013;52</p></caption><table frame="vsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Total</th><th align="center" valign="bottom" colspan="3" rowspan="1">Vaccine Failure<sup>a</sup></th><th align="center" valign="bottom" colspan="3" rowspan="1">P[8] Vaccine Failure<sup>b</sup></th><th align="center" valign="bottom" colspan="3" rowspan="1">P[6] Vaccine Failure<sup>b</sup></th><th align="center" valign="bottom" colspan="3" rowspan="1">P[4] Vaccine Failure<sup>b</sup></th></tr><tr><th valign="bottom" rowspan="1" colspan="1">Phenotype</th><th align="center" valign="bottom" rowspan="1" colspan="1">No. (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">No. (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">RR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>Q</italic> Value</th><th align="center" valign="bottom" rowspan="1" colspan="1">No. (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">RR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>Q</italic> Value</th><th align="center" valign="bottom" rowspan="1" colspan="1">No. (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">RR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>Q</italic> Value</th><th align="center" valign="bottom" rowspan="1" colspan="1">No. (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">RR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>Q</italic> Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic>Se</italic>
</td><td rowspan="1" colspan="1">189 (69)</td><td rowspan="1" colspan="1">35 (75)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">21 (75)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2 (29)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">11 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<italic>se</italic>
</td><td rowspan="1" colspan="1">86 (31)</td><td rowspan="1" colspan="1">12 (25)</td><td rowspan="1" colspan="1">0.75 (.41&#x02013;1.38)</td><td rowspan="1" colspan="1">0.49</td><td rowspan="1" colspan="1">7 (25)</td><td rowspan="1" colspan="1">0.74 (.33&#x02013;1.67)</td><td rowspan="1" colspan="1">0.55</td><td rowspan="1" colspan="1">5 (71)</td><td rowspan="1" colspan="1">5.53 (1.10&#x02013;27.9)</td><td rowspan="1" colspan="1">0.066</td><td rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">0.066</td></tr><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">275 (100)</td><td rowspan="1" colspan="1">47 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">28 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">7 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">11 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td colspan="14" rowspan="1">
<italic>Se</italic>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Le<sup>+</sup></td><td rowspan="1" colspan="1">155 (82)</td><td rowspan="1" colspan="1">33 (94)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">21 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">11 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Le<sup>&#x02013;</sup></td><td rowspan="1" colspan="1">34 (18)</td><td rowspan="1" colspan="1">2 (6)</td><td rowspan="1" colspan="1">0.28 (.070&#x02013;1.10)</td><td rowspan="1" colspan="1">0.066</td><td rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">0.066</td><td rowspan="1" colspan="1">2 (100)</td><td align="center" rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">0.066</td><td rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">0.30</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Total</td><td rowspan="1" colspan="1">189 (100)</td><td rowspan="1" colspan="1">35 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">21 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">11 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td colspan="14" rowspan="1">
<italic>se</italic>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Le<sup>+</sup></td><td rowspan="1" colspan="1">73 (85)</td><td rowspan="1" colspan="1">8 (67)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">7 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1 (20)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Le<sup>&#x02013;</sup></td><td rowspan="1" colspan="1">13 (15)</td><td rowspan="1" colspan="1">4 (33)</td><td rowspan="1" colspan="1">2.81 (.99&#x02013;7.99)</td><td rowspan="1" colspan="1">0.12</td><td rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">0.6</td><td rowspan="1" colspan="1">4 (80)</td><td rowspan="1" colspan="1">22.2 (2.69&#x02013;183)</td><td rowspan="1" colspan="1">0.022</td><td rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Total</td><td rowspan="1" colspan="1">86 (100)</td><td rowspan="1" colspan="1">12 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">7 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5 (100)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="fn-11"><p>
<italic>Q</italic> values calculated by adjustment of raw <italic>P</italic> values (&#x003c7;<sup>2</sup> or Fisher exact test) for multiple comparisons by the Benjamini&#x02013;Hochberg procedure.</p></fn><fn id="fn-12"><p>Abbreviations: CI, confidence interval; Le<sup>+</sup>, Lewis-positive; Le<sup>&#x02013;</sup>, Lewis-negative; NA, not applicable; RR, relative risk; <italic>Se</italic>, secretor; <italic>se</italic>, nonsecretor.</p></fn><fn id="fn-13"><p>
<sup>a</sup>Children who experienced at least 1 episode of breakthrough RVD, irrespective of P genotype.</p></fn><fn id="fn-14"><p>
<sup>b</sup>Second episodes of RVD due to a different P genotype from the first are included, but second episodes due to the same P genotype are not since susceptibility to that specific P genotype had already been confirmed with the prior episode. Untypeable specimens were excluded from analysis. Therefore, the total number of P genotype&#x02013;specific episodes differs from the total number of children with any RVD.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s15"><title>DISCUSSION</title><p>This is the first study to investigate the effects of secretor status and Lewis phenotype on risk of RVD in South Asia and the first to assess their impact on estimates of oral RV VE. Our results provide several highly significant findings. Most importantly, we demonstrate in a cohort of Bangladeshi infants that nonsecretor status is associated with reduced risk of RVD in the absence of vaccination (<xref ref-type="table" rid="T4">Table 4</xref>; <xref ref-type="fig" rid="F2">Figure 2B</xref>). This effect reduced estimates of VE, and was mediated not by reduced susceptibility to P[8] RVD as previously reported [<xref rid="CIT0009" ref-type="bibr">9&#x02013;11</xref>, <xref rid="CIT0022" ref-type="bibr">22&#x02013;24</xref>], but rather by complete protection from P[4] RV (<xref ref-type="table" rid="T4">Table 4</xref>). These findings may have significant implications in the interpretation of past RV VE studies and in the design of future trials. In addition, we provide further evidence of increased susceptibility to P[6] RVD among Le<sup>&#x02013;</sup> infants (<xref ref-type="table" rid="T4">Table 4</xref>). While this did not alter overall susceptibility to RVD in this cohort, which experienced few P[6] infections, this effect could have a larger impact in regions with greater frequencies of P[6] RVD and Le<sup>&#x02013;</sup> individuals.</p><p>VE is calculated as [(risk among unvaccinated &#x02013; risk among vaccinated) / risk among unvaccinated]. Decreased risk of infection in the unvaccinated group therefore decreases VE. In this study, resistance to RVD among unvaccinated nonsecretors decreased the risk of RVD in the unvaccinated group, thereby reducing VE. Overall per-protocol VE in PROVIDE was 51% (95% CI, 33.5%&#x02013;64%) against any RVD [<xref rid="CIT0014" ref-type="bibr">14</xref>]. However, we show here that VE in nonsecretors was lower (31.7%) than in secretors (56.2%). It might be expected that the effect of nonsecretor status would be equivalent across both the vaccinated and unvaccinated arms of the study and thus not have any overall effect [<xref rid="CIT0025" ref-type="bibr">25</xref>]. However, the effect we observed was clearly unequal. Since RVD risk among vaccine recipients was already substantially reduced due to vaccination, the incremental effect of natural resistance was proportionally smaller, leading to a smaller risk reduction.</p><p>This unexpected mechanism by which VE calculations might be affected could have a significant impact in regions with high frequencies of nonsecretors and P[4] RV infections. This appears to be the case in Bangladesh, where we found that 32.5% of the population (<xref ref-type="table" rid="T1">Table 1</xref>) was nonsecretor, compared to 20% of the white population [<xref rid="CIT0026" ref-type="bibr">26</xref>]. These results carry important implications, as they suggest that at least some degree of the decreased VE estimates observed in LICs may be due to lack of accounting for the effect of nonsecretor status on overall susceptibility to RVD in the placebo arms of VE trials. Secretor status, Lewis phenotype, and RV genotype should thus be accounted for in future oral RV vaccine trials, as has been suggested for norovirus trials [<xref rid="CIT0025" ref-type="bibr">25</xref>], and previous VE estimates may need to be adjusted in regions most likely to be impacted by this effect.</p><p>The reduced risk of RVD among nonsecretors appeared to be mediated by resistance to P[4] RV. Despite being the second most common infecting strain in most regions [<xref rid="CIT0012" ref-type="bibr">12</xref>], P[4] RV infections have been underrepresented in previous studies assessing RVD and secretor status or Lewis phenotype. In limited sample sizes, others have reported that P[4] RVD only occurred among secretors [<xref rid="CIT0008" ref-type="bibr">8</xref>, <xref rid="CIT0009" ref-type="bibr">9</xref>, <xref rid="CIT0011" ref-type="bibr">11</xref>, <xref rid="CIT0023" ref-type="bibr">23</xref>, <xref rid="CIT0024" ref-type="bibr">24</xref>]. Our study represents the largest number of P[4] infections reported to date in this body of literature and provides evidence that nonsecretors may be naturally resistant to infection from P[4], but not P[8], RVs. Our findings are consistent with previous reports on RV genotype diversity and HBGA distributions in Bangladesh [<xref rid="CIT0019" ref-type="bibr">19</xref>, <xref rid="CIT0027" ref-type="bibr">27</xref>, <xref rid="CIT0028" ref-type="bibr">28</xref>], supporting their generalizability in Bangladesh.</p><p>We found no evidence that nonsecretors were resistant to P[8] RVD (<xref ref-type="table" rid="T4">Table 4</xref>). Since RV1 contains an attenuated P[8] strain of RV, this suggests that nonsecretors are unlikely to be resistant to infection from vaccine-strain virus. This is supported by our finding that vaccinated nonsecretors were not at increased risk for vaccine failure compared to secretors and thus were afforded a similar degree of protection by RV1 (<xref ref-type="table" rid="T5">Table 5</xref>). Demonstration of similar frequencies of vaccine take by measurement of postvaccination fecal RV1 shedding and RV-specific IgA seroconversion in nonsecretors and secretors would strengthen these findings and is an important topic for future investigation. If confirmed, this would suggest that resistance to oral vaccines containing attenuated P[8] viruses is an unlikely mechanism for reduced VE in LICs. One prior study in Pakistan reported that nonsecretors had the lowest frequency of RV1 vaccine take in that population, but did not include efficacy data [<xref rid="CIT0029" ref-type="bibr">29</xref>].</p><p>There are several possibilities for why we did not detect any differences in P[8] RVD according to secretor status. First, previous studies identified cases of RVD based on passive surveillance, biasing toward more severe cases. Our study identified cases via active community surveillance, potentially identifying more mild cases. It is possible that nonsecretor status may limit the severity of P[8] RVD but be permissive of milder infection. However, we did detect severe P[8] RVD in our cohort (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table 1</xref>). It is also possible that unique strains of P[8] RV may differ in their ability to infect nonsecretors. In this cohort, 26 of 29 P[8] infections (90%) among nonsecretors were due to the same G9P[8] strain (GenBank KP902551.1). Differences in circulating P[8] RV strains might affect regional differences in susceptibility to P[8] RVs.</p><p>In contrast to secretor status, Lewis phenotype did not appear to impact VE (<xref ref-type="table" rid="T4">Table 4</xref> and <xref ref-type="fig" rid="F2">Figure 2A</xref>). However, our data further support previous findings from Burkina Faso, Nicaragua, and Tunisia that demonstrated an increased risk for P[6] RVD among Le<sup>&#x02013;</sup> infants [<xref rid="CIT0008" ref-type="bibr">8</xref>, <xref rid="CIT0011" ref-type="bibr">11</xref>]. Similarly, we also observed that Le<sup>&#x02013;</sup> infants had fewer P[8] RV infections [<xref rid="CIT0008" ref-type="bibr">8</xref>, <xref rid="CIT0011" ref-type="bibr">11</xref>]; this effect appeared strongest among secretors, possibly due to sample size (<xref ref-type="table" rid="T4">Table 4</xref>). However, in our cohort, this effect was offset by a markedly increased risk of P[6] RVD among Le<sup>&#x02013;</sup> infants (<xref ref-type="table" rid="T4">Table 4</xref>). Le<sup>&#x02013;</sup> infants were also protected from P[4] RVD, although this effect was weaker than that afforded by nonsecretor status. Furthermore, since removal of P[4] infections did not alter overall RVD risk according to Lewis phenotype, we submit that secretor status was the more relevant P genotype effect. However, it is possible that a Lewis phenotype effect for P[4] RVD also exists that we were unable to explicitly demonstrate.</p><p>Together, our findings underscore that the P genotype environment may have important implications for vaccine performance in different regions. In this Bangladeshi cohort, P[4] RVs had a significant impact according to secretor status. However, despite increased susceptibility among Le<sup>&#x02013;</sup> infants, P[6] RVs did not have a significant impact on overall risk of RVD due to the small number of P[6] RV infections observed. We also had relatively few Le<sup>&#x02013;</sup> infants in our study, further supporting the hypothesis that regional P[6] RV burden may reflect the population frequency of Le<sup>&#x02013;</sup> individuals. Furthermore, while results should be interpreted with caution due to sample size, our data suggest that RV1 conferred less protection against P[6] RVD compared to P[8] or P[4] (<xref ref-type="table" rid="T5">Table 5</xref> and <xref ref-type="supplementary-material" rid="sup2">Supplementary Table 2</xref>). If this study were conducted in Africa, where P[6] infections and Le<sup>&#x02013;</sup> phenotypes are more common [<xref rid="CIT0011" ref-type="bibr">11</xref>, <xref rid="CIT0012" ref-type="bibr">12</xref>], our results could have been changed considerably. In these locations, VE could be diminished by increased vaccine failure due to P[6] RVD. Additional efforts to characterize RV-HBGA associations in diverse settings are thus warranted [<xref rid="CIT0007" ref-type="bibr">7</xref>].</p><p>This study has several limitations. First, this was a substudy of a larger VE study. Selection bias was likely limited, however, as 93% (n = 550/593) of the per-protocol parent cohort was represented. Our results were less significant for severe RVD, the primary outcome for most RV VE trials. As noted above, this is likely due to the smaller number of severe infections we encountered, limiting power. Due to inherent limitations in HBGA phenotype assays, some individuals may have been misclassified. However, our secondary validation between Lewis antigen and secretor status assays suggests this was unlikely. Confirmation via host genotype analysis would strengthen these findings but was beyond the scope of this work and is another topic for future investigation. We did not detect any mixed infections, as our sequencing approach likely selected for the most dominant strain if multiple strains were present. Although undetected mixed infections could affect these results, our results likely reflect the dominant and thus most clinically relevant genotypes. Finally, this study assessed RV1, so results may not be generalizable to other RV vaccines.</p><p>In conclusion, we demonstrate in a cohort of Bangladeshi infants that nonsecretors were at decreased risk of RVD due to complete protection from P[4] RVs. This effect could significantly impact estimates of VE, particularly in regions with high frequencies of nonsecretors and P[4] RV. We found no evidence of resistance to P[8] RVs as a mechanism for decreased VE. Le<sup>&#x02013;</sup> infants appeared to be protected from P[8] RVD, but this effect was offset by a markedly increased risk for RVD and vaccine failure due to P[6] infection. Secretor status, Lewis phenotype, and RV genotype should be accounted for in future oral RV vaccine trials.</p></sec><sec sec-type="supplementary-material" id="s16"><title>Supplementary Data</title><p>Supplementary materials are available at <italic>The Journal of Infectious Diseases</italic> online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.</p><supplementary-material content-type="local-data" id="sup1"><label>Supplementary Table 1</label><media xlink:href="jiy054_suppl_supplementary_table_1.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sup2"><label>Supplementary Table 2</label><media xlink:href="jiy054_suppl_supplementary_table_2.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sup3"><label>Supplementary Figure 1</label><media xlink:href="jiy054_suppl_supplementary_figure_1.pptx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><notes id="n1"><title>Notes</title><p>
<bold><italic>Acknowledgments.</italic></bold> We thank the PROVIDE study families and study staff for making this work possible and Timothy Hunt, Scott Tighe, and Jessica Hoffman of the University of Vermont Advanced Genome Technologies Core Facility for their assistance with RV strain sequencing. </p><p>
<bold><italic>Potential conflicts of interest.</italic></bold> All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</p><p>
<bold><italic>Financial support.</italic></bold> This work was supported by the Bill &#x00026; Melinda Gates Foundation (grant numbers OPP1127782 to B. D. K. and OPP1017093); the National Institutes of Health (grant number AI043596 to W. A. P.); the International Centre for Diarrhoeal Disease Research, Bangladesh; and the governments of Bangladesh, Canada, Sweden, and the United Kingdom (core/unrestricted support).</p><p>Presented in part: 66th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Baltimore, Maryland, 7 November 2017.</p></notes><ref-list><title>References</title><ref id="CIT0001"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Platts-Mills</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Juma</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study</article-title>. <source>Lancet</source><year>2016</year>; <volume>388</volume>:<fpage>1291</fpage>&#x02013;<lpage>301</lpage>.<pub-id pub-id-type="pmid">27673470</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tate</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Burton</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Boschi-Pinto</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Parashar</surname><given-names>UD</given-names></name></person-group>
<article-title>Global, regional, and national estimates of rotavirus mortality in children &#x0003c;5 years of age, 2000&#x02013;2013</article-title>. <source>Clin Infect Dis</source><year>2016</year>; <volume>62</volume>:<fpage>S96</fpage>&#x02013;<lpage>105</lpage>.<pub-id pub-id-type="pmid">27059362</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jonesteller</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Burnett</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Yen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Tate</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Parashar</surname><given-names>UD</given-names></name></person-group>
<article-title>Effectiveness of rotavirus vaccination: a systematic review of the first decade of global post-licensure data, 2006&#x02013;2016</article-title>. <source>Clin Infect Dis</source><year>2017</year>; <volume>65</volume>:<fpage>840</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">28444323</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Spike protein VP8* of human rotavirus recognizes histo-blood group antigens in a type-specific manner</article-title>. <source>J Virol</source><year>2012</year>; <volume>86</volume>:<fpage>4833</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">22345472</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Patnaik</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Helmberg</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Blumenfeld</surname><given-names>OO</given-names></name></person-group>
<article-title>BGMUT database of allelic variants of genes encoding human blood group antigens</article-title>. <source>Transfus Med Hemother</source><year>2014</year>; <volume>41</volume>:<fpage>346</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">25538536</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>M</given-names></name></person-group>
<article-title>Histo-blood group antigens as receptors for rotavirus, new understanding on rotavirus epidemiology and vaccine strategy</article-title>. <source>Emerg Microbes Infect</source><year>2017</year>; <volume>6</volume>:<fpage>e22</fpage>.<pub-id pub-id-type="pmid">28400594</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kambhampati</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Payne</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Costantini</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Lopman</surname><given-names>BA</given-names></name></person-group>
<article-title>Host genetic susceptibility to enteric viruses: a systematic review and metaanalysis</article-title>. <source>Clin Infect Dis</source><year>2016</year>; <volume>62</volume>:<fpage>11</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">26508510</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ayouni</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sdiri-Loulizi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>de Rougemont</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Rotavirus P[8] infections in persons with secretor and nonsecretor phenotypes, Tunisia</article-title>. <source>Emerg Infect Dis</source><year>2015</year>; <volume>21</volume>:<fpage>2055</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">26488868</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Rotavirus infection and histo-blood group antigens in the children hospitalized with diarrhoea in China</article-title>. <source>Clin Microbiol Infect</source><year>2016</year>; <volume>22</volume>:<fpage>740.e1&#x02013;3</fpage>.<pub-id pub-id-type="pmid">27345178</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>XF</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>P[8] and P[4] rotavirus infection associated with secretor phenotypes among children in South China</article-title>. <source>Sci Rep</source><year>2016</year>; <volume>6</volume>:<fpage>34591</fpage>.<pub-id pub-id-type="pmid">27708367</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nordgren</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bucardo</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Both Lewis and secretor status mediate susceptibility to rotavirus infections in a rotavirus genotype-dependent manner</article-title>. <source>Clin Infect Dis</source><year>2014</year>; <volume>59</volume>:<fpage>1567</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">25097083</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hoshino</surname><given-names>Y</given-names></name></person-group>
<article-title>Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine</article-title>. <source>Rev Med Virol</source><year>2005</year>; <volume>15</volume>:<fpage>29</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">15484186</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ruuska</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Vesikari</surname><given-names>T</given-names></name></person-group>
<article-title>Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes</article-title>. <source>Scand J Infect Dis</source><year>1990</year>; <volume>22</volume>:<fpage>259</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">2371542</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Colgate</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Haque</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Dickson</surname><given-names>DM</given-names></name><etal>et al</etal></person-group>
<article-title>Delayed dosing of oral rotavirus vaccine demonstrates decreased risk of rotavirus gastroenteritis associated with serum zinc: a randomized controlled trial</article-title>. <source>Clin Infect Dis</source><year>2016</year>; <volume>63</volume>:<fpage>634</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">27217217</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kirkpatrick</surname><given-names>BD</given-names></name>, <name name-style="western"><surname>Colgate</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Mychaleckyj</surname><given-names>JC</given-names></name><etal>et al</etal></person-group>
<person-group><collab>PROVIDE Study Teams</collab></person-group>
<article-title>The &#x0201c;Performance of Rotavirus and Oral Polio Vaccines in Developing Countries&#x0201d; (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems</article-title>. <source>Am J Trop Med Hyg</source><year>2015</year>; <volume>92</volume>:<fpage>744</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">25711607</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Naylor</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Haque</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<person-group><collab>PROVIDE Study Teams</collab></person-group>
<article-title>Environmental enteropathy, oral vaccine failure and growth faltering in infants in Bangladesh</article-title>. <source>EBioMedicine</source><year>2015</year>; <volume>2</volume>:<fpage>1759</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">26870801</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gratz</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Amour</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Optimization of quantitative PCR methods for enteropathogen detection</article-title>. <source>PLoS One</source><year>2016</year>; <volume>11</volume>:<fpage>e0158199</fpage>.<pub-id pub-id-type="pmid">27336160</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Simmonds</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Armah</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Asmah</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>New oligonucleotide primers for P-typing of rotavirus strains: strategies for typing previously untypeable strains</article-title>. <source>J Clin Virol</source><year>2008</year>; <volume>42</volume>:<fpage>368</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">18378188</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Lundgren</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Arifuzzaman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Qadri</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Teneberg</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Svennerholm</surname><given-names>AM</given-names></name></person-group>
<article-title>Children with the Le(a+b-) blood group have increased susceptibility to diarrhea caused by enterotoxigenic <italic>Escherichia coli</italic> expressing colonization factor I group fimbriae</article-title>. <source>Infect Immun</source><year>2009</year>; <volume>77</volume>:<fpage>2059</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">19273560</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Benjamini</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hochberg</surname><given-names>Y</given-names></name></person-group>
<article-title>Controlling the false discovery rate&#x02014;a practical and powerful approach to multiple testing</article-title>. <source>J Roy Stat Soc B Met</source><year>1995</year>; <volume>57</volume>:<fpage>289</fpage>&#x02013;<lpage>300</lpage>.</mixed-citation></ref><ref id="CIT0021"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Verkerke</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sobuz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>JZ</given-names></name><etal>et al</etal></person-group>
<article-title>Malnutrition is associated with protection from rotavirus diarrhea: evidence from a longitudinal birth cohort study in Bangladesh</article-title>. <source>J Clin Microbiol</source><year>2016</year>; <volume>54</volume>:<fpage>2568</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">27510830</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Imbert-Marcille</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Barb&#x000e9;</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Dup&#x000e9;</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>A FUT2 gene common polymorphism determines resistance to rotavirus A of the P[8] genotype</article-title>. <source>J Infect Dis</source><year>2014</year>; <volume>209</volume>:<fpage>1227</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">24277741</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Payne</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Currier</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Staat</surname><given-names>MA</given-names></name><etal>et al</etal></person-group>
<article-title>Epidemiologic association between FUT2 secretor status and severe rotavirus gastroenteritis in children in the United States</article-title>. <source>JAMA Pediatr</source><year>2015</year>; <volume>169</volume>:<fpage>1040</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">26389824</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Van Trang</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Vu</surname><given-names>HT</given-names></name>, <name name-style="western"><surname>Le</surname><given-names>NT</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Anh</surname><given-names>DD</given-names></name></person-group>
<article-title>Association between norovirus and rotavirus infection and histo-blood group antigen types in Vietnamese children</article-title>. <source>J Clin Microbiol</source><year>2014</year>; <volume>52</volume>:<fpage>1366</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">24523471</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nordgren</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kambhampati</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lopman</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Svensson</surname><given-names>L</given-names></name></person-group>
<article-title>Innate resistance and susceptibility to norovirus infection</article-title>. <source>PLoS Pathog</source><year>2016</year>; <volume>12</volume>:<fpage>e1005385</fpage>.<pub-id pub-id-type="pmid">27115484</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Daniels</surname><given-names>G.</given-names></name></person-group>
<source>Human blood groups</source>. <edition>2nd ed</edition>
<publisher-loc>Oxford</publisher-loc>: <publisher-name>Blackwell Science Ltd</publisher-name>, <year>2002</year>.</mixed-citation></ref><ref id="CIT0027"><label>27.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Akhter</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kibria</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Akhter</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Habibullah</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Islam</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zakariah</surname><given-names>M</given-names></name></person-group>
<article-title>ABO and Lewis blood grouping with ABH secretor and non-secretor status: a cross sectional study in Dhaka</article-title>. <source>Faridpur Med Coll J</source><year>2011</year>; <volume>6</volume>:<fpage>38</fpage>&#x02013;<lpage>40</lpage>.</mixed-citation></ref><ref id="CIT0028"><label>28.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Satter</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Gastanaduy</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Islam</surname><given-names>K</given-names></name><etal>et al</etal></person-group>
<article-title>Hospital-based surveillance for rotavirus gastroenteritis among young children in Bangladesh: defining the potential impact of a rotavirus vaccine program</article-title>. <source>Pediatr Infect Dis J</source><year>2017</year>; <volume>36</volume>:<fpage>168</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">27798545</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kazi</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Cortese</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><etal>et al</etal></person-group>
<article-title>Secretor and salivary ABO blood group antigen status predict rotavirus vaccine take in infants</article-title>. <source>J Infect Dis</source><year>2017</year>; <volume>215</volume>:<fpage>786</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28329092</pub-id></mixed-citation></ref></ref-list></back></article>